Tins STUDY evolved from two recent developments at the Hospital for Sick Children, Toronto. The first was the avoidance of explosive anaesthetic agents for routine clinical practice. The second was the introduction into clinical use of a new endotracheal aerosol with a metering system which could deliver accurate doses of lidocaine. 1
Tins STUDY evolved from two recent developments at the Hospital for Sick Children, Toronto. The first was the avoidance of explosive anaesthetic agents for routine clinical practice. The second was the introduction into clinical use of a new endotracheal aerosol with a metering system which could deliver accurate doses of lidocaine. 1 Previously, 4 per cent lidocaine was administered to the glottic and tracheal regions from a Macintosh spray. With this method, toxic blood levels could readily be reached in small infants from rapid absorption or from overdose. Foldes et aI. 2 investigated the acute toxicity of lldocahae following intravenous infusion. Objective signs of toxicity developed after an average dose of 6.4 mg/kg with a corresponding serum concentration of 5.29 -+-0.55 ftg/ml. Using 4 per cent lidocaine, Bromage et al? showed that the rate of absorption from the larynx and trachea varied. Following a dose of 3.5 to 10.5 mg/kg, peak blood concentrations occurred in 5 to 25 minutes. Bromage observed no toxic signs, although serum concentration did reach 10 ftg/ml in one case. He stated that statistically there is one chance in 20 that the concentration will reach 10 /zg/ml when a dose of 6 mg/kg is given jntratracheally. Therefore, he recommended that the dosage should be below this amount.
METHODS

Examination of the dosage form
Prior to clinical investigation, a study was undertaken to ascertain the accuracy of the manufacturer's claims for delivery of an accurately metered dose of lidocaine (10 mg per actuation). The samples were taken from six aerosol bombs equipped with unit dose dispensers (Emson MP-20-PC, 50 ml) and an 8 inch nozzle, such assemblies being drawn from retail sources. Each aerosol bomb held 22 grams of a 20 per cent w/w solution of lidocaine base in a solvent-propellant mixtare composed of absolute alcohol (3.95 gin), propylene glycol (2.50 mg), Freon 12 (3 gin) and Freon 114 (5.6 gin). The nozzle effluents from each valve actuation were trapped in a mixture of 7 ml of N/100 sulphuric acid, 3 ml ethanol, and 0.25 ml of bromocresol green-methyl red indicator (u.s.P. xvI). The excess sulphuric acid was back-titrated with N/100 sodium hydroxide solution to a blue-green colour (pH 4.5). One in ten determina- tions consisted of a blank of the sulphuric acid/ethanol/indicator mixture, and three standards consisting of pure lidocaine base were run as controls.
The results of this study are shown in Table I . It is apparent that, with the exception of the first six and the last twenty sprays, the aerosol dispenser delivers a dose of lidocaine of approximately 10 rag. We consider the scatter about this mean value to be safe from a clinical standpoint. It should be mentioned here that other investigators 4,~ have studied unit-dose aerosol medications in a more comprehensive way. Their observations are in agreement with our own in that they found weight variations of delivered dosages to be of the order of ---+ 10 per cent within containers (depending on the composition of the propellant and the construction of the valve) and greater than 10 per cent between container mean 
Clinical investigation
Based on the above findings, a topical dosage corresponding to 3 mg/kg was introduced with satisfactory topical anaesthesia. The rate and degree of systemic absorption from tracheal and bronchial mucosa were established from arterial and venous blood levels of lidocaine. These blood levels were correlated with the appearance of any toxic signs.
Thirteen cardiovascular patients were used in this study. The cardiovascular lesions were limited to patients with aortic stenosis, pulmonary stenosis, or coarctation of the aorta. These patients were selected because they were in good condition, had non-shunting lesions, and routinely had indwelling arterial and venous pressure lines inserted.
In all patients, premedication consisted of intramuscular atropine and meperidine, plus pentobarbital administered either by the intramuscular route or by suppository. The patients were induced with intravenous 2.5 per cent sodium thiopentone. Anaesthesia was maintained with nitrous oxide, oxygen, and halothane with spontaneous respiration, using a face mask with a modified Ayre's T-piece or Magill circuit with a non-rebreathing valve. The arterial and central venous catheters were then inserted. After the administration of succinylcholine, a lidocaine aerosol bomb with an 8 inch nozzle was used to deliver a total dose of 3 mg/kg. The first spray was delivered directly to the larynx and subsequent sprays were administered below the level of the vocal cords. All patients were then intubated without difficulty using non-lubricated endotracheal tubes, and anaesthesia was maintained using controlled ventilation.
Throughout the entire procedure, physiological parameters were monitored using BP cuff apparatus, arterial and venous pressures, ECG, EEC, and serial blood gas measurements.
Arterial and venous samples (3 ml) were taken at intervals following the administration of lidocaine. They were heparinized and stored at 4 ~ C until they were assayed. Lidocaine levels were determined using the gas chromatograph method described by Keenaghan. 6 The values obtained, using prilocaine as an internal reference standard, were corrected for artifacts by standardizing against blood of known lidocaine concentration. Figures 1 and 2 show the results obtained.
RESULTS
Although there were 13 patients in the series, 13 separate venous and arterial results were not obtained at each time interval because of technical difficulties in obtaining samples in some cases. In a few, the laboratory reported a partially clotted sample, so results were discarded as their accuracy could not be vouched for. Values were obtained for the amount of lidocaine in the arterial blood of each of the patients one minute after spraying, and a mean value was taken. This was repeated for each of the time values. A graph was made of these points ( 1) and it displays a rise in the arterial value with a maximum in two minutes, followed by a gradual fall. The standard error for each of these points was calculated and is indicated by a bar across the point, in order to show the degree of scatter of the various values about the mean. This is fairly wide at those points where there were fewer observations. A similar process was followed for the venous levels at the various times. A
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DISCUSSION
This investigation included (a) the determination of lidocaine content in aerosol sprays, (b) the study of uptake of lidocaine from the tracheobronchial mucosa, (c) the maximum levels obtained in systemic arterial and venous blood, (d) the rate of disappearance of lidocaine, and (e) the correlation of any toxic signs to the blood concentration.
Thomas et al. r state that blood concentrations were independent of dose in their investigation of absorption of lidoeaine topically from the vagina, introitus, perineum, and episiotomy repair sights. Similarly, Bromage z states that from his resuits, the rate of absorption from the trachea was not predictable. Gianelly et al. 8 concluded that the concentration of lidocaine in the blood following intravenous administration was directly related to the dose given. They also concluded that an effective safe blood level of 2 to 5/zg/ml is obtained by an intravenous bolus of 1 to 2 mg/kg, and that maior side effects may occur with blood levels of 9/zg/ ml. Adriani 9 asserts that the topical anaesthetic agents applied to the pharynx and trachea are readily absorbed from the pulmonary alveoli. The resultant blood levels correlate well with the concentration following rapid intravenous injection. From our study, the concentration of lidocaine in the blood was directly related to the dose administered. Our doses averaged 3 mg/kg, with a maximum of 3.6 mg/kg.
Maximum levels found in arterial blood were 2.5/zg/ml, and in venous blood 3.2/zg/ml. These are below the safe level noted above. The blood levels fell progressively with time, as shown. It is di~cult to ascertain where the major degree of absorption occurs; that is, at the mucosa of the trachea and bronchi or at the pulmonary alveoli. It is probably safe to say that the rate of absorption is dependent upon the state of the mucosa, the amount of mucous present in the airways, the rate and depth of respiration, the state of the circulation, and the total dose given. In the dose range used with the 10 per cent lidocaine spray, toxic blood levels were not reached and no signs of toxicity occurred.
Tomashefski et al. 1~ reported on the development and use of an aerosol using 10 per cent lidocaine in oropharyngeal and tracheobronchial anaesthesia. The mass mean particle size of the lidoeaine spray was 5 microns. They felt that this size would allow a more even dispersion of the anaesthetic agent through the moving air column and permit deposition on the mucosa throughout most of the tracheobronchial tree. They noted no adverse effects from the use of 10 per cent lidocaine solution applied topically.
Concern has been expressed by some individuals with respect to the effects of a 10 per cent lidocaine solution on the mueosa and cilia. However, Corssen ix has shown that lidocaine has a low toxicity on cultured human respiratory epithelium in concentrations up to 20 per cent. It would thus appear that the concentration used in this aerosol will have no permanent effect on mueosa/n vivo.
CONCLUSION
As an adjunct to general anaesthesia, the technique of using topical lidocaine on the tracheobronchial mucosa is effective and reliable and obtunds laryngeal reflexes. The blood concentrations are dose dependent and in the dosage used (3 mg/kg), the blood concentrations are below toxic levels and are safe.
R~SUM~
Comme adjuvant h l'anesth6sie g6n6rale, rusage de la lidocaine topique sur la muqueuse trach6obronchique est efllcace et m6rite qu'on s'y arr~te; cette technique ~mousse les r6flexes laryng6s. Les concentrations dans le sang d6pendent de la dose; dans le dosage que nous avons utilis6 (3 mg/kg), les concentrations sanguines sont inf~rieures aux niveaux toxiques et sans danger.
